Antituberculous vaccine development: a perspective for the endemic world

References

• Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur. Respir. J.26(1), 162–167 (2005).
   PubMed Web of Science ®Google Scholar
• Hesseling AC, Marais BJ, Gie RP et al. The risk of disseminated bacille Calmette–Guérin (BCG) disease in HIV-infected children. Vaccine25(1), 14–18 (2007).
   PubMed Web of Science ®Google Scholar
• Black GF, Weir RE, Floyd S et al. BCG-induced increase in interferon-g response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet359(9315), 1393–1401 (2002).
   PubMed Web of Science ®Google Scholar
• McShane H. Vaccine strategies against tuberculosis. Swiss Med. Wkly139(11–12), 156–160 (2009).
   PubMed Web of Science ®Google Scholar
• Andersen P, Doherty TM. The success and failure of BCG – implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol.3(8), 656–662 (2005).
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost–effectiveness. Lancet367, 1173–1180 (2006).
   PubMed Web of Science ®Google Scholar
• Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai, India. Indian J. Med. Res.110, 56–69 (1999).
   PubMed Web of Science ®Google Scholar
• Behr MA, Small PM. Has BCG attenuated to impotence? Nature389(6647), 133–134 (1997).
   PubMed Web of Science ®Google Scholar
• Lozes E, Denis O, Drowart A et al. Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group. Scand. J. Immunol.46(1), 16–26 (1997).
   PubMedGoogle Scholar
• Brandt L, Feino Cunha J, Weinreich Olsen A et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun.70(2), 672–678 (2002).
   PubMed Web of Science ®Google Scholar
• Buddle BM, Wards BJ, Aldwell FE, Collins DM, de Lisle GW. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine20(7–8), 1126–1133 (2002).
   PubMed Web of Science ®Google Scholar
• Leung CC, Tam CM, Chan SL, Chan-Yeung M, Chan CK, Chang KC. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int. J. Tuberc. Lung Dis.5(8), 717–723 (2001).
   PubMed Web of Science ®Google Scholar
• Kamala T, Paramasivan CN, Herbert D, Venkatesan P, Prabhakar R. Immune response and modulation of immune response induced in the guinea-pigs by Mycobacterium avium complex (MAC) and M. fortuitum complex isolates from different sources in the south Indian BCG trial area. Indian J. Med. Res.103, 201–211 (1996).
   PubMed Web of Science ®Google Scholar
• McMurray DN. Recent progress in the development and testing of vaccines against human tuberculosis. Int. J. Parasitol.33(5–6), 547–554 (2003).
   PubMed Web of Science ®Google Scholar
• Lin MY, Ottenhoff TH. Host–pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention. Endocr. Metab. Immune Disord. Drug Targets8(1), 15–29 (2008).
   PubMedGoogle Scholar
• Brennan MJ. The tuberculosis vaccine challenge. Tubeculosis85 (1–2), 7–12 (2005).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun.71(4), 1672–1679 (2003).
   PubMed Web of Science ®Google Scholar
• Demangel C, Garnier T, Rosenkrands I, Cole ST. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect. Immun.73(4), 2190–2196 (2005).
   PubMed Web of Science ®Google Scholar
• Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette–Guérin mutants that secrete listeriolysin. J. Clin. Invest.115(9), 2472–2479 (2005).
   PubMed Web of Science ®Google Scholar
• Sun R, Skeiky YA, Izzo A et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine27(33), 4412–4423 (2009).
   PubMed Web of Science ®Google Scholar
• Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol. Microbiol.41(1), 179–187 (2001).
   PubMed Web of Science ®Google Scholar
• Martin C, Williams A, Hernandez-Pando R et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine24(17), 3408–3419 (2006).
   PubMed Web of Science ®Google Scholar
• Sambandamurthy VK, Derrick SC, Hsu T et al.Mycobacterium tuberculosis δRD1 δpanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine24(37–39), 6309–6320 (2006).
   PubMed Web of Science ®Google Scholar
• Pinto R, Saunders BM, Camacho LR, Britton WJ, Gicquel B, Triccas JA. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette–Guérin vaccine. J. Infect. Dis.189(1), 105–112 (2004).
   PubMed Web of Science ®Google Scholar
• Hinchey J, Lee S, Jeon BY et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest.117(8), 2279–2288 (2007).
   PubMed Web of Science ®Google Scholar
• Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette–Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171(3), 1602–1609 (2003).
   PubMed Web of Science ®Google Scholar
• Brandt L, Skeiky YA, Alderson MR et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun.72(11), 6622–6632 (2004).
   PubMed Web of Science ®Google Scholar
• Elvang T, Christensen JP, Billeskov R et al. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS ONE4(4), e5139 (2009).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–Guérin immunity. J. Immunol.177(9), 6353–6360 (2006).
   PubMed Web of Science ®Google Scholar
• Beveridge NE, Price DA, Casazza JP et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur. J. Immunol.37(11), 3089–3100 (2007).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74(8), 4634–4643 (2006).
   PubMed Web of Science ®Google Scholar
• Kalra M, Grover A, Mehta N et al. Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clin. Immunol.125(2), 173–183 (2007).
   PubMedGoogle Scholar
• Lowrie DB, Tascon RE, Bonato VL et al. Therapy of tuberculosis in mice by DNA vaccination. Nature400(6741), 269–271 (1999).
   PubMed Web of Science ®Google Scholar
• Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun.71(4), 2192–2198 (2003).
   PubMed Web of Science ®Google Scholar
• Henao-Tamayo M, Palaniswamy GS, Smith EE et al. Post-exposure vaccination against Mycobacterium tuberculosis. Tuberculosis (Edinb.)89(2), 142–148 (2009).
   PubMed Web of Science ®Google Scholar
• Giri PK, Verma I, Khuller GK. Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection. Immunotherapy1, 31–37 (2009).
   PubMedGoogle Scholar
• Sable SB, Kumar R, Kalra M et al. Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect. Immun.73(6), 3547–3558 (2005).
   PubMedGoogle Scholar
• Cardona PJ, Amat I, Gordillo S et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine23(11), 1393–1398 (2005).
   PubMed Web of Science ®Google Scholar
• Stanford JL, Bahr GM, Rook GA et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle71(2), 87–93 (1990).
   PubMedGoogle Scholar